Publication: Enhanced mRNA expression of plasminogen activator inhibitor-1 in livedoid vasculopathy lesions
| dc.contributor.author | AKKİPRİK, MUSTAFA | |
| dc.contributor.authors | Agirbasli, Mehmet; Goktay, Fatih; Peker, Irem; Gunes, Pembegul; Aker, Fugen Vardar; Akkiprik, Mustafa | |
| dc.date.accessioned | 2022-03-12T22:23:56Z | |
| dc.date.accessioned | 2026-01-11T07:11:34Z | |
| dc.date.available | 2022-03-12T22:23:56Z | |
| dc.date.issued | 2017 | |
| dc.description.abstract | AimThrombosis and inflammation play an important role in pathophysiology of livedoid vasculopathy (LV). Plasminogen activator inhibitor-1 (PAI-1) is the main physiological inhibitor of fibrinolysis and is a pivotal modulator in a broad range of biological processes. MethodThe study specimens were retrospectively selected from archives of pathology department. We investigated PAI-1 mRNA expression in the paraffin blocks of patients with biopsy-proven LV and controls. We analyzed the presence of thrombus, fibrinoid necrosis, ulcer, and epidermal atrophy in study samples. The correlation between histologic findings and PAI-1 expression was investigated. ResultsAnalyses were performed in 14 LV patients (mean age 3120, 79% female) and 4 controls (mean age 64 +/- 19, 50% female). PAI-1 gene expression was significantly higher in LV compared to the control group (median 7.74 (Iqr:13.94) vs 1.0 (0.31)), P=.011. Histological analysis displayed that fibrinoid necrosis was present on all patients with LV, 61.5% displayed thrombus, 46.2% displayed ulcer, and 15.4% displayed epidermal atrophy. Overall, we did not observe any discerning difference in PAI-1 expression between the LV blocks with or without thrombus, fibrinoid necrosis, or epidermal atrophy, yet the LV specimens that displayed ulcer histologically had higher PAI-1 mRNA expression compared to those without ulcer (median 13.98 (Iqr:19.21) vs 2.86 (5.59)), (P=.046). ConclusionPAI-1 mRNA expression is significantly increased in cutaneous lesions of patients with LV. Histological finding of ulcer is associated with increased PAI-1 expression in LV specimen. In the current era of PAI-1 inhibitors, enhanced local PAI-1 expression can form a novel and local therapeutic target in LV. | |
| dc.identifier.doi | 10.1111/1755-5922.12255 | |
| dc.identifier.eissn | 1755-5922 | |
| dc.identifier.issn | 1755-5914 | |
| dc.identifier.pubmed | 28186689 | |
| dc.identifier.uri | https://hdl.handle.net/11424/234615 | |
| dc.identifier.wos | WOS:000401193000007 | |
| dc.language.iso | eng | |
| dc.publisher | WILEY | |
| dc.relation.ispartof | CARDIOVASCULAR THERAPEUTICS | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | Fibrinolysis | |
| dc.subject | Plasminogen activator inhibitor 1 | |
| dc.subject | Plasminogen inactivators | |
| dc.subject | Thrombosis | |
| dc.subject | Topical administration | |
| dc.subject | Vascular diseases | |
| dc.subject | VASCULITIS | |
| dc.subject | DISEASE | |
| dc.subject | PAI-1 | |
| dc.subject | POPULATION | |
| dc.subject | MUTATION | |
| dc.subject | LEIDEN | |
| dc.title | Enhanced mRNA expression of plasminogen activator inhibitor-1 in livedoid vasculopathy lesions | |
| dc.type | article | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | 3 | |
| oaire.citation.title | CARDIOVASCULAR THERAPEUTICS | |
| oaire.citation.volume | 35 |
